---
company: KALA BIO, Inc.
ticker: KALA
form: 8-K
filed: 2026-11-09
accepted: 2026-11-09T14:01:35+00:00
accession: 0001829126-26-012118
source: https://www.sec.gov/Archives/edgar/data/1479419/000182912626012118/
---

# KALA BIO (KALA) Q3 2026 earnings

## Header

- Company: KALA BIO, Inc.
- Reported: 2026-11-09 09:01 BMO ET
- Source: 8-K only — accession 0001829126-26-012118, Item 2.02 + Exhibit 99.1
- Verdict: Reduced quarterly net loss by approximately 90% year over year.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---|---|---|
| Revenue | $0.0 | — | — | Ex. 99.1, Preliminary Results |
| EPS (GAAP) | $0.00 | — | — | Ex. 99.1, Preliminary Results |
| EPS (adjusted) | $0.00 | — | — | Ex. 99.1, Preliminary Results |
| Net income | $0.0 | — | — | Ex. 99.1, Preliminary Results |
| Adj. EBITDA | $0.0 | — | — | Ex. 99.1, Preliminary Results |
| Adj. EBITDA margin | 0.0% | — | — | Ex. 99.1, Preliminary Results |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: not stated in the 8-K
- One-offs in the quarter: not stated in the 8-K
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---|---|---|
| Net loss | $0.0 | — | — | Reduced by approximately 90% year over year |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: No revenue figures stated.
- EPS story: No EPS figures stated.
- One-off check: No one-off items disclosed.

## The good

- Reduced quarterly net loss by approximately 90% year over year

## The bad

- none

## The ugly

- none

## Open questions

- What were the prior year's net loss figures to calculate the 90% reduction?
- What were the revenue, net income, and EPS figures for the quarter?
- What were the adjusted EBITDA and margin figures for the quarter?

## Full release

### KALA BIO (KALA) earnings release, November 9, 2026

KALA BIO, Inc. (KALA) · Form 8-K, Item 2.02 · Filed 2026-11-09 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1479419/000182912626012118/)

KALA

BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results

New

York, November 9, 2026 – KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026.

Preliminary

Third Quarter 2026 Results

“We reduced our quarterly net loss by approximately 90% year over year and continue to develop the initiatives we have put in motion. We thank our stockholders who attended our Annual Meeting on November 3, 2026, and for their continued support,” said Avi Minkowitz,

Chief Executive Officer and Chief Financial Officer.

KALA expects to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 with the SEC on or about November 16, 2026.

Preliminary

Results

The results above are preliminary, unaudited and subject to completion of the Company’s financial close procedures and review by its independent registered public accounting firm. Final results, to be included in the Form 10-Q, may differ.

About

Kala Bio, Inc. (NASDAQ: KALA)

KALA

BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome

(MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business that deploys secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The

Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.

Kala believes the future of biomedical innovation is in agentic systems.

For more information, visit www.kalarx.com and Researgency.ai

Forward-Looking

Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s preliminary unaudited financial results for the three and nine months ended September 30, 2026 and the expected timing of the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

The preliminary financial results set forth in this press release are based on management’s current estimates and information available as of the date of this release. They are unaudited and remain subject to the completion of the Company’s financial closing procedures, final adjustments, and review by the Company’s independent registered public accounting firm. The Company’s actual results may differ materially from these preliminary results, and these preliminary results should not be viewed as a substitute for the full interim financial statements to be included in the Form 10-Q.

Important factors that could cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to: adjustments arising from the completion of the Company’s financial closing procedures or the review of its interim financial statements; the identification of subsequent events or additional information prior to the filing of the Form

10-Q; delays in the completion or filing of the Form 10-Q; and other risks detailed in the “Risk Factors” section of the

Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as may be updated in the Company’s Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Avi

Minkowitz

Chief Executive Officer, KALA BIO, Inc. am@kalarx.com www.kalarx.com

|

www.Researgency.ai
